HIV-1 gene therapy (Takara Bio)

N/A

Report date: 2024/09/06 14:17:53

Base Information

Drug NameHIV-1 gene therapy (Takara Bio)

Drug Alias NameMazF gene therapy

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionGene transferenceT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTakara Bio Inc University Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of Pennsylvania

Active IndicationsN/A

Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A